Novo Nordisk’s New Insulin Tresiba to Take on Lantus in 2016

Novo Nordisk’s insulin degludec injection, known by the brand name Tresiba, met with FDA approval in late September. It is expected to be available to patients with a doctor’s prescription in the first few months of 2016, according to Novo Nordisk’s chief medical officer for North America, Dr. Todd Hobbs.

Read more

Posted in Glucose & Insulin